报价延迟最少15分钟:2026/11/04 17:03 EST
盘后时段
|
||||
|
1.17 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.17
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.64/-1.37
|
|
企业价值
188.74M
|
| 资产负债 |
|
每股账面净值
0.41
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
72.95M
|
|
每股收益
0.16
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications. |
